Article Details
Retrieved on: 2025-01-27 15:23:01
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Cartesian Therapeutics' progress in regenerative medicine through mRNA therapy for autoimmune diseases, focusing on Descartes-08's Phase 3 trial for myasthenia gravis. The trial's design was approved under FDA's SPA, highlighting its potential.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here